This individual is no longer a medical reviewer in our network. The credentials and information reflected above are only associated with other freelance roles the individual may currently hold.\n"},"avatar":{"title":"","width":500,"height":500,"src":"https://post.healthline.com/wp-content/uploads/2022/01/Jill-Seladi-Schulman-500x500-Bio.png"}}],"medicalReviewers":[{"id":6679,"name":{"display":"Angela Ryan Lee, MD, FACC","first":"Angela Ryan","last":"Lee, MD, FACC"},"userLogin":"arlee","links":{"website":"","facebook":"","linkedin":"https://www.linkedin.com/in/angela-ryan-lee-md-facc-682174145/","twitter":"","instagram":"https://www.instagram.com/dr_lee_heartmd/","tiktok":""},"link":"/reviewers/angela-ryan-lee-md-facc","type":{"value":"medical_reviewer","label":"Medical Advisor"},"nid":"","specialties":[],"guestTitle":"","bio":{"text":"
People with atrial fibrillation are at a higher risk of blood clots. Blood thinners may help prevent blood clots from forming.
Atrial fibrillation (AFib) is a type of arrythmia in which the upper chambers of the heart, called the atria, beat irregularly and too quickly. This effects your heartâs ability to pump blood effectively.
In AFib, blood can pool in the heart, increasing the risk that blood clots will form. These clots can travel to other parts of the body, such as the brain, lungs, or kidney, where they can cause serious health issues.
Many people with AFib use blood thinners to help prevent blood clots from forming.
The effects of AFib can promote the formation of blood clots that can travel to other areas of the body and block off blood vessels. When this happens, the affected area cannot get enough oxygen-rich blood and damage can occur.
One of the major complications of AFib is ischemic stroke, which happens when a blood vessel in the brain is blocked. Itâs estimated that people with AFib have a fivefold increased risk of stroke.
Blood thinners are a drug that helps to prevent blood clots from forming. You may also see them called anticoagulants.
To help reduce the risk of stroke and other clot-related complications from AFib, your doctor may prescribe a blood thinner. These medications can help to reduce the risk of stroke by more than 50% and also prevent stroke recurrence.
There are several types of blood thinners used for AFib. One is warfarin (Coumadin), a blood thinner called a vitamin K antagonist. Warfarin is taken orally.
Your daily dose of warfarin is based on your bodyâs response to a particular dose. An international normalized ratio (INR) blood test determines your appropriate dose and to adjust dosing as needed.
Your INR is measured frequently when you begin taking warfarin, and can be measured less frequently once a stable dose is determined.
Direct-acting oral anticoagulants (DOACs) are another blood thinner used for AFib. Most guidelines give preference to these drugs over warfarin. There are several DOACs available:
DOACs are also taken orally. Depending on the DOAC prescribed, youâll take it once or twice daily.
Unlike warfarin, DOACs have fixed doses and do not require lab monitoring. In some cases, these medications are better than warfarin at reducing stroke and have less bleeding complications.
The main complication of using blood thinners for AFib is the risk of bleeding. This is because blood thinners affect your bloodâs ability to clot.
Most of the time, this bleeding is minor. For example, if you cut your finger, it may take your blood longer to clot.
However, bleeding can also be more severe and potentially life threatening. This can include bleeding in your digestive system or inside of your skull.
Many people with AFib take blood thinners to reduce their risk of stroke or other complications due to blood clots. These drugs work by reducing the bloodâs ability to clot.
Not everyone with AFib needs blood thinners.
Your doctor will estimate your stroke risk before recommending blood thinners. Because blood thinners can cause potentially serious bleeding, doctors will also assess your bleeding risk.
How we reviewed this article:
Healthline has strict sourcing guidelines and relies on peer-reviewed studies, academic research institutions, and medical journals and associations. We only use quality, credible sources to ensure content accuracy and integrity. You can learn more about how we ensure our content is accurate and current by reading our editorial policy.
January CT, et al. (2019). 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. https://www.ahajournals.org/doi/10.1161/CIR.0000000000000665
Zhu W, et al. (2015). The HAS‐BLED score for predicting major bleeding risk in anticoagulated patients with atrial fibrillation: A systematic review and meta‐analysis. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6490831/